Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell' from ‘Hold', citing concerns that its recent valuation is difficult to justify. Citi raised its price target to $80 from $60 while revising its sales and operating expense assumptions.
Read on invezz.com